These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30418122)

  • 1. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis.
    Fassio A; Gatti D; Rossini M; Idolazzi L; Giollo A; Adami G; Gisondi P; Girolomoni G; Viapiana O
    Clin Exp Rheumatol; 2019; 37(1):133-136. PubMed ID: 30418122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
    Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
    Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study.
    Fassio A; Adami G; Giollo A; Viapiana O; Malavolta N; Saviola G; Bortolotti R; Idolazzi L; Bertoldo F; Rossini M; Gatti D
    Calcif Tissue Int; 2020 Apr; 106(4):371-377. PubMed ID: 31897527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum Dickkopf-1 is a biomarker for bone erosion in patients with psoriatic arthritis.
    Chung Y; Li ZC; Sun XL; Liu YY; Shao M; Gan YZ; Li YM; Li YH; Zhang XW
    Chin Med J (Engl); 2021 Jul; 134(21):2583-2588. PubMed ID: 34267065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study.
    Jadon DR; Sengupta R; Nightingale A; Lu H; Dunphy J; Green A; Elder JT; Nair RP; Korendowych E; Lindsay MA; McHugh NJ
    Arthritis Res Ther; 2017 Sep; 19(1):210. PubMed ID: 28934972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators.
    Fassio A; Adami G; Gatti D; Orsolini G; Giollo A; Idolazzi L; Benini C; Vantaggiato E; Rossini M; Viapiana O
    Int Immunopharmacol; 2019 Feb; 67():487-489. PubMed ID: 30599401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment.
    Fassio A; Adami G; Idolazzi L; Giollo A; Viapiana O; Vantaggiato E; Benini C; Rossini M; Dejaco C; Gatti D
    Front Med (Lausanne); 2020; 7():551. PubMed ID: 33015101
    [No Abstract]   [Full Text] [Related]  

  • 10. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
    Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
    Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
    Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
    Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
    Daoussis D; Liossis SN; Solomou EE; Tsanaktsi A; Bounia K; Karampetsou M; Yiannopoulos G; Andonopoulos AP
    Arthritis Rheum; 2010 Jan; 62(1):150-8. PubMed ID: 20039407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile.
    Sato K; Aizaki Y; Yoshida Y; Mimura T
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):181-185. PubMed ID: 33086998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E; d'Oliveira I; Linz C; Lerchen V; Stemmler F; Simon D; Englbrecht M; Sticherling M; Rech J; Kleyer A; Schett G; Hueber AJ
    Arthritis Res Ther; 2018 Jul; 20(1):153. PubMed ID: 30053825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of secukinumab on serum adipocytokines: preliminary data.
    Fassio A; Gatti D; Gisondi P; Girolomoni G; Viapiana O; Giollo A; Zamboni M; Rossini M; Idolazzi L
    Reumatismo; 2017 Sep; 69(3):105-110. PubMed ID: 28933132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
    Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
    Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.